Across all clinical experience, the reported maximum single dose received was 90 mg. Bone marrow aplasia, infections, or severe infusions reactions occurred in patients who received a dose higher than recommended.
One patient received an 80 mg dose by IV infusion and experienced acute bronchospasm, cough, and dyspnea, followed by anuria and death. Another patient received two 90 mg doses by IV infusion one day apart during the second week of treatment and experienced a rapid onset of bone marrow aplasia.
There is no known specific antidote for Mab-Campath overdosage. Treatment consists of drug discontinuation and supportive therapy.
Across all clinical experience, the reported maximum single dose received was 90 mg. Bone marrow aplasia, infections, or severe infusions reactions occurred in patients who received a dose higher than recommended.
One patient received an 80 mg dose by IV infusion and experienced acute bronchospasm, cough, and dyspnea, followed by anuria and death. Another patient received two 90 mg doses by IV infusion one day apart during the second week of treatment and experienced a rapid onset of bone marrow aplasia.
There is no known specific antidote for Campath overdosage. Treatment consists of drug discontinuation and supportive therapy.
None
The following adverse reactions are discussed in greater detail in other sections of the label:
The most common adverse reactions with Mab-Campath are: infusion reactions (pyrexia, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), infections (CMV viremia, CMV infection, other infections), gastrointestinal symptoms (nausea, emesis, abdominal pain), and neurological symptoms (insomnia, anxiety). The most common serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections.
Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data below reflect exposure to Mab-Campath in 296 patients with CLL of whom 147 were previously untreated and 149 received at least 2 prior chemotherapy regimens. The median duration of exposure was 11.7 weeks for previously untreated patients and 8 weeks for previously treated patients.
LymphopeniaSevere lymphopenia and a rapid and sustained decrease in lymphocyte subsets occurred in previously untreated and previously treated patients following administration of Mab-Campath. In previously untreated patients, the median CD4+ was 0 cells/µL at one month after treatment and 238 cells/µL [25-75% interquartile range 115 to 418 cells/µL at 6 months post-treatment.
NeutropeniaIn previously untreated patients, the incidence of Grade 3 or 4 neutropenia was 42% with a median time to onset of 31 days and a median duration of 37 days. In previously treated patients, the incidence of Grade 3 or 4 neutropenia was 64% with a median duration of 28 days. Ten percent of previously untreated patients and 17% of previously treated patients received granulocyte colony stimulating factors.
AnemiaIn previously untreated patients, the incidence of Grade 3 or 4 anemia was 12% with a median time to onset of 31 days and a median duration of 8 days. In previously treated patients, the incidence of Grade 3 or 4 anemia was 38%. Seventeen percent of previously untreated patients and 66% of previously treated patients received either erythropoiesis stimulating agents, transfusions or both.
ThrombocytopeniaIn previously untreated patients, the incidence of Grade 3 or 4 thrombocytopenia was 14% with a median time to onset of 9 days and a median duration of 14 days. In previously treated patients, the incidence of Grade 3 or 4 thrombocytopenia was 52% with a median duration of 21 days. Autoimmune thrombocytopenia was reported in 2% of previously treated patients with one fatality.
Infusion reactionsInfusion reactions, which included pyrexia, chills, hypotension, urticaria, and dyspnea, were common. Grade 3 and 4 pyrexia and/or chills occurred in approximately 10% of previously untreated patients and in approximately 35% of previously treated patients. The occurrence of infusion reactions was greatest during the initial week of treatment and decreased with subsequent doses of Mab-Campath. All patients were pretreated with antipyretics and antihistamines; additionally, 43% of previously untreated patients received glucocorticoid pre-treatment.
InfectionsIn the study of previously untreated patients, patients were tested weekly for CMV using a PCR assay from initiation through completion of therapy, and every 2 weeks for the first 2 months following therapy. CMV infection occurred in 16% (23/147) of previously untreated patients; approximately one-third of these infections were serious or life threatening. In studies of previously treated patients in which routine CMV surveillance was not required, CMV infection was documented in 6% (9/149) of patients; nearly all of these infections were serious or life threatening.
Other infections were reported in approximately 50% of patients across all studies. Grade 3 - 5 sepsis ranged from 3% to 10% across studies and was higher in previously treated patients. Grade 3 - 4 febrile neutropenia ranged from 5 to 10% across studies and was higher in previously treated patients. Infection-related fatalities occurred in 2% of previously untreated patients and 16% of previously treated patients. There were 198 episodes of other infection in 109 previously untreated patients; 16% were bacterial, 7% were fungal, 4% were other viral, and in 73%, the organism was not identified.
CardiacCardiac dysrhythmias occurred in approximately 14% of previously untreated patients. The majority were tachycardias and were temporally associated with infusion; dysrhythmias were Grade 3 or 4 in 1% of patients.
Previously Untreated PatientsTable 1 contains selected adverse reactions observed in 294 patients randomized (1:1) to receive Mab-Campath or chlorambucil as first line therapy for B-CLL. Mab-Campath was administered at a dose of 30 mg intravenously three times weekly for up to 12 weeks. The median duration of therapy was 11.7 weeks with a median weekly dose of 82 mg (25-75% interquartile range: 69 mg - 90 mg).
Table 1
| Per Patient Incidence of Selected1 Adverse Reactions in Treatment Naive B-CLL Patients | |||||
| Mab-Campath (n=147) | Chlorambucil (n=147) | ||||
| All Grades2 % | Grades 3-4 % | All Grades % | Grades 3-4 % | ||
| Blood and Lymphatic System Disorders | Lymphopenia | 97 | 97 | 9 | 1 |
| Neutropenia | 77 | 42 | 51 | 26 | |
| Anemia | 76 | 13 | 54 | 18 | |
| Thrombocytopenia | 71 | 13 | 70 | 14 | |
| General Disorders and Administration Site Conditions | Pyrexia | 69 | 10 | 11 | 1 |
| Chills | 53 | 3 | 1 | 0 | |
| Infections and Infestations | CMV viremia3 | 55 | 4 | 8 | 0 |
| CMV infection | 16 | 5 | 0 | 0 | |
| Other infections | 74 | 21 | 65 | 10 | |
| Skin and Subcutaneous Tissue Disorders | Urticaria | 16 | 2 | 1 | 0 |
| Rash | 13 | 1 | 4 | 0 | |
| Erythema | 4 | 0 | 1 | 0 | |
| Vascular Disorders | Hypotension | 16 | 1 | 0 | 0 |
| Hypertension | 14 | 5 | 2 | 1 | |
| Nervous System Disorders | Headache | 14 | 1 | 8 | 0 |
| Tremor | 3 | 0 | 1 | 0 | |
| Respiratory, Thoracic and Mediastinal Disorders | Dyspnea | 14 | 4 | 7 | 3 |
| Gastrointestinal Disorders | Diarrhea | 10 | 1 | 4 | 0 |
| Psychiatric Disorders | Insomnia | 10 | 0 | 3 | 0 |
| Anxiety | 8 | 0 | 1 | 0 | |
| Cardiac Disorders | Tachycardia | 10 | 0 | 1 | 0 |
| 1Adverse reactions occurring at a higher relative frequency in the Mab-Campath arm 2NCI CTC version 2.0 for adverse reactions; NCI CTCAE version 3.0 for laboratory values 3CMV viremia (without evidence of symptoms) includes both cases of single PCR positive test results and of confirmed CMV viremia ( ≥ 2 occasions in consecutive samples 1 week apart). For the latter, ganciclovir (or equivalent) was initiated per protocol. |
Additional safety information was obtained from 3 single arm studies of 149 previously treated patients with CLL administered 30 mg Mab-Campath intravenously three times weekly for 4 to 12 weeks (median cumulative dose 673 mg [range 2 - 1106 mg]; median duration of therapy 8.0 weeks). Adverse reactions in these studies not listed in Table 1 that occurred at an incidence rate of > 5% were fatigue, nausea, emesis, musculoskeletal pain, anorexia, dysesthesia, mucositis, and bronchospasm.
ImmunogenicityAs with all therapeutic proteins, there is potential for immunogenicity. Using an ELISA assay, anti-human antibodies (HAHA) were detected in 11 of 133 (8.3%) previously untreated patients. In addition, two patients were weakly positive for neutralizing activity. Limited data suggest that the anti-Mab-Campath antibodies did not adversely affect tumor response. Four of 211 (1.9%) previously-treated patients were found to have antibodies to Mab-Campath following treatment.
The incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Mab-Campath with the incidence of antibodies to other products may be misleading.
Postmarketing ExperienceThe following adverse reactions were identified during post-approval use of Mab-Campath. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Mab-Campath exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) reported frequency of the reaction, or (3) strength of causal connection to Mab-Campath.
Fatal infusion reactions:.
Cardiovascular: congestive heart failure, cardiomyopathy, decreased ejection fraction (some patients had been previously treated with cardiotoxic agents).
Immune disorders: Goodpasture's syndrome, Graves' disease, aplastic anemia, Guillain Barre syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, serum sickness, fatal transfusion associated Graft versus Host Disease.
Infections: Epstein-Barr Virus (EBV) including EBV-associated lymphoproliferative disorder, progressive multifocal leukoencephalopathy (PML), re-activation of latent viruses.
Metabolic: tumor lysis syndrome
Neurologic: optic neuropathy
The following adverse reactions are discussed in greater detail in other sections of the label:
The most common adverse reactions with Campath are: infusion reactions (pyrexia, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), infections (CMV viremia, CMV infection, other infections), gastrointestinal symptoms (nausea, emesis, abdominal pain), and neurological symptoms (insomnia, anxiety). The most common serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections.
Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data below reflect exposure to Campath in 296 patients with CLL of whom 147 were previously untreated and 149 received at least 2 prior chemotherapy regimens. The median duration of exposure was 11.7 weeks for previously untreated patients and 8 weeks for previously treated patients.
LymphopeniaSevere lymphopenia and a rapid and sustained decrease in lymphocyte subsets occurred in previously untreated and previously treated patients following administration of Campath. In previously untreated patients, the median CD4+ was 0 cells/µL at one month after treatment and 238 cells/µL [25-75% interquartile range 115 to 418 cells/µL at 6 months post-treatment.
NeutropeniaIn previously untreated patients, the incidence of Grade 3 or 4 neutropenia was 42% with a median time to onset of 31 days and a median duration of 37 days. In previously treated patients, the incidence of Grade 3 or 4 neutropenia was 64% with a median duration of 28 days. Ten percent of previously untreated patients and 17% of previously treated patients received granulocyte colony stimulating factors.
AnemiaIn previously untreated patients, the incidence of Grade 3 or 4 anemia was 12% with a median time to onset of 31 days and a median duration of 8 days. In previously treated patients, the incidence of Grade 3 or 4 anemia was 38%. Seventeen percent of previously untreated patients and 66% of previously treated patients received either erythropoiesis stimulating agents, transfusions or both.
ThrombocytopeniaIn previously untreated patients, the incidence of Grade 3 or 4 thrombocytopenia was 14% with a median time to onset of 9 days and a median duration of 14 days. In previously treated patients, the incidence of Grade 3 or 4 thrombocytopenia was 52% with a median duration of 21 days. Autoimmune thrombocytopenia was reported in 2% of previously treated patients with one fatality.
Infusion reactionsInfusion reactions, which included pyrexia, chills, hypotension, urticaria, and dyspnea, were common. Grade 3 and 4 pyrexia and/or chills occurred in approximately 10% of previously untreated patients and in approximately 35% of previously treated patients. The occurrence of infusion reactions was greatest during the initial week of treatment and decreased with subsequent doses of Campath. All patients were pretreated with antipyretics and antihistamines; additionally, 43% of previously untreated patients received glucocorticoid pre-treatment.
InfectionsIn the study of previously untreated patients, patients were tested weekly for CMV using a PCR assay from initiation through completion of therapy, and every 2 weeks for the first 2 months following therapy. CMV infection occurred in 16% (23/147) of previously untreated patients; approximately one-third of these infections were serious or life threatening. In studies of previously treated patients in which routine CMV surveillance was not required, CMV infection was documented in 6% (9/149) of patients; nearly all of these infections were serious or life threatening.
Other infections were reported in approximately 50% of patients across all studies. Grade 3 - 5 sepsis ranged from 3% to 10% across studies and was higher in previously treated patients. Grade 3 - 4 febrile neutropenia ranged from 5 to 10% across studies and was higher in previously treated patients. Infection-related fatalities occurred in 2% of previously untreated patients and 16% of previously treated patients. There were 198 episodes of other infection in 109 previously untreated patients; 16% were bacterial, 7% were fungal, 4% were other viral, and in 73%, the organism was not identified.
CardiacCardiac dysrhythmias occurred in approximately 14% of previously untreated patients. The majority were tachycardias and were temporally associated with infusion; dysrhythmias were Grade 3 or 4 in 1% of patients.
Previously Untreated PatientsTable 1 contains selected adverse reactions observed in 294 patients randomized (1:1) to receive Campath or chlorambucil as first line therapy for B-CLL. Campath was administered at a dose of 30 mg intravenously three times weekly for up to 12 weeks. The median duration of therapy was 11.7 weeks with a median weekly dose of 82 mg (25-75% interquartile range: 69 mg - 90 mg).
Table 1
| Per Patient Incidence of Selected1 Adverse Reactions in Treatment Naive B-CLL Patients | |||||
| Campath (n=147) | Chlorambucil (n=147) | ||||
| All Grades2 % | Grades 3-4 % | All Grades % | Grades 3-4 % | ||
| Blood and Lymphatic System Disorders | Lymphopenia | 97 | 97 | 9 | 1 |
| Neutropenia | 77 | 42 | 51 | 26 | |
| Anemia | 76 | 13 | 54 | 18 | |
| Thrombocytopenia | 71 | 13 | 70 | 14 | |
| General Disorders and Administration Site Conditions | Pyrexia | 69 | 10 | 11 | 1 |
| Chills | 53 | 3 | 1 | 0 | |
| Infections and Infestations | CMV viremia3 | 55 | 4 | 8 | 0 |
| CMV infection | 16 | 5 | 0 | 0 | |
| Other infections | 74 | 21 | 65 | 10 | |
| Skin and Subcutaneous Tissue Disorders | Urticaria | 16 | 2 | 1 | 0 |
| Rash | 13 | 1 | 4 | 0 | |
| Erythema | 4 | 0 | 1 | 0 | |
| Vascular Disorders | Hypotension | 16 | 1 | 0 | 0 |
| Hypertension | 14 | 5 | 2 | 1 | |
| Nervous System Disorders | Headache | 14 | 1 | 8 | 0 |
| Tremor | 3 | 0 | 1 | 0 | |
| Respiratory, Thoracic and Mediastinal Disorders | Dyspnea | 14 | 4 | 7 | 3 |
| Gastrointestinal Disorders | Diarrhea | 10 | 1 | 4 | 0 |
| Psychiatric Disorders | Insomnia | 10 | 0 | 3 | 0 |
| Anxiety | 8 | 0 | 1 | 0 | |
| Cardiac Disorders | Tachycardia | 10 | 0 | 1 | 0 |
| 1Adverse reactions occurring at a higher relative frequency in the Campath arm 2NCI CTC version 2.0 for adverse reactions; NCI CTCAE version 3.0 for laboratory values 3CMV viremia (without evidence of symptoms) includes both cases of single PCR positive test results and of confirmed CMV viremia ( ≥ 2 occasions in consecutive samples 1 week apart). For the latter, ganciclovir (or equivalent) was initiated per protocol. |
Additional safety information was obtained from 3 single arm studies of 149 previously treated patients with CLL administered 30 mg Campath intravenously three times weekly for 4 to 12 weeks (median cumulative dose 673 mg [range 2 - 1106 mg]; median duration of therapy 8.0 weeks). Adverse reactions in these studies not listed in Table 1 that occurred at an incidence rate of > 5% were fatigue, nausea, emesis, musculoskeletal pain, anorexia, dysesthesia, mucositis, and bronchospasm.
ImmunogenicityAs with all therapeutic proteins, there is potential for immunogenicity. Using an ELISA assay, anti-human antibodies (HAHA) were detected in 11 of 133 (8.3%) previously untreated patients. In addition, two patients were weakly positive for neutralizing activity. Limited data suggest that the anti-Campath antibodies did not adversely affect tumor response. Four of 211 (1.9%) previously-treated patients were found to have antibodies to Campath following treatment.
The incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Campath with the incidence of antibodies to other products may be misleading.
Postmarketing ExperienceThe following adverse reactions were identified during post-approval use of Campath. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Campath exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) reported frequency of the reaction, or (3) strength of causal connection to Campath.
Fatal infusion reactions:.
Cardiovascular: congestive heart failure, cardiomyopathy, decreased ejection fraction (some patients had been previously treated with cardiotoxic agents).
Immune disorders: Goodpasture's syndrome, Graves' disease, aplastic anemia, Guillain Barre syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, serum sickness, fatal transfusion associated Graft versus Host Disease.
Infections: Epstein-Barr Virus (EBV) including EBV-associated lymphoproliferative disorder, progressive multifocal leukoencephalopathy (PML), re-activation of latent viruses.
Metabolic: tumor lysis syndrome
Neurologic: optic neuropathy
Mab-Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).
Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).
The effect of multiple doses of alemtuzumab (12 mg/day for 5 days) on the QTc interval was evaluated in a single-arm study in 53 patients without malignancy. No large changes in the mean QTc interval (i.e., > 20 ms) were detected in the study. A mean increase in heart rate of 22 to 26 beats/min was observed for at least 2 hours following the initial infusion of alemtuzumab. This increase in heart rate was not observed with subsequent doses.
Mab-Campath pharmacokinetics were characterized in a study of 30 previously treated B-CLL patients in whom Mab-Campath was administered at the recommended dose and schedule. Mab-Campath pharmacokinetics displayed nonlinear elimination kinetics. After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg). Systemic clearance decreased with repeated administration due to decreased receptor-mediated clearance (i.e., loss of CD52 receptors in the periphery). After 12 weeks of dosing, patients exhibited a seven-fold increase in mean AUC. Mean half-life was 11 hours (range 2 to 32 hours) after the first 30 mg dose and was 6 days (range 1 to 14 days) after the last 30 mg dose.
Comparisons of AUC in patients ≥ 65 years (n=6) versus patients < 65 years (n=15) suggested that no dose adjustments are necessary for age. Comparisons of AUC in female patients (n=4) versus male patients (n=17) suggested that no dose adjustments are necessary for gender.
The pharmacokinetics of Mab-Campath in pediatric patients have not been studied. The effects of renal or hepatic impairment on the pharmacokinetics of Mab-Campath have not been studied.
Campath pharmacokinetics were characterized in a study of 30 previously treated B-CLL patients in whom Campath was administered at the recommended dose and schedule. Campath pharmacokinetics displayed nonlinear elimination kinetics. After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg). Systemic clearance decreased with repeated administration due to decreased receptor-mediated clearance (i.e., loss of CD52 receptors in the periphery). After 12 weeks of dosing, patients exhibited a seven-fold increase in mean AUC. Mean half-life was 11 hours (range 2 to 32 hours) after the first 30 mg dose and was 6 days (range 1 to 14 days) after the last 30 mg dose.
Comparisons of AUC in patients ≥ 65 years (n=6) versus patients < 65 years (n=15) suggested that no dose adjustments are necessary for age. Comparisons of AUC in female patients (n=4) versus male patients (n=17) suggested that no dose adjustments are necessary for gender.
The pharmacokinetics of Campath in pediatric patients have not been studied. The effects of renal or hepatic impairment on the pharmacokinetics of Campath have not been studied.
Included as part of the PRECAUTIONS section.
PRECAUTIONS CytopeniasSevere, including fatal, autoimmune anemia and thrombocytopenia, and prolonged myelosuppression have been reported in patients receiving Mab-Campath.
In addition, hemolytic anemia, pure red cell aplasia, bone marrow aplasia, and hypoplasia have been reported after treatment with Mab-Campath at the recommended dose. Single doses of Mab-Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of pancytopenia.
Withhold Mab-Campath for severe cytopenias (except lymphopenia). Discontinue for autoimmune cytopenias or recurrent/persistent severe cytopenias (except lymphopenia). No data exist on the safety of Mab-Campath resumption in patients with autoimmune cytopenias or marrow aplasia.
Infusion ReactionsAdverse reactions occurring during or shortly after Mab-Campath infusion include pyrexia, chills/rigors, nausea, hypotension, urticaria, dyspnea, rash, emesis, and bronchospasm. In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Monitor for the signs and symptoms listed above and withhold infusion for Grade 3 or 4 infusion reactions.
The following serious, including fatal, infusion reactions have been identified in postmarketing reports: syncope, pulmonary infiltrates, acute respiratory distress syndrome (ARDS), respiratory arrest, cardiac arrhythmias, myocardial infarction, acute cardiac insufficiency, cardiac arrest, angioedema, and anaphylactoid shock.
Initiate Mab-Campath according to the recommended dose-escalation scheme. Premedicate patients with an antihistamine and acetaminophen prior to dosing. Institute medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion reactions as needed. If therapy is interrupted for 7 or more days, reinstitute Mab-Campath with gradual dose escalation.
Immunosuppression/InfectionsMab-Campath treatment results in severe and prolonged lymphopenia with a concomitant increased incidence of opportunistic infections. Administer PCP and herpes viral prophylaxis during Mab-Campath therapy and for a minimum of 2 months after completion of Mab-Campath or until the CD4+ count is ≥ 200 cells/µL, whichever occurs later. Prophylaxis does not eliminate these infections.
Routinely monitor patients for CMV infection during Mab-Campath treatment and for at least 2 months following completion of treatment. Withhold Mab-Campath for serious infections and during antiviral treatment for CMV infection or confirmed CMV viremia (defined as polymerase chain reaction (PCR) positive CMV in ≥ 2 consecutive samples obtained 1 week apart). Initiate therapeutic ganciclovir (or equivalent) for CMV infection or confirmed CMV viremia.
Administer only irradiated blood products to avoid transfusion associated Graft versus Host Disease (TAGVHD), unless emergent circumstances dictate immediate transfusion.1
In patients receiving Mab-Campath as initial therapy, recovery of CD4+ counts to ≥ 200 cells/µL occurred by 6 months post-treatment; however at 2 months post-treatment, the median was 183 cells/µL. In previously treated patients receiving Mab-Campath, the median time to recovery of CD4+ counts to ≥ 200 cells/µ.L was 2 months; however, full recovery (to baseline) of CD4+ and CD8+ counts may take more than 12 months.
Laboratory MonitoringObtain complete blood counts (CBC) at weekly intervals during Mab-Campath therapy and more frequently if worsening anemia, neutropenia, or thrombocytopenia occurs. Assess CD4+ counts after treatment until recovery to ≥ 200 cells/µL.
ImmunizationThe safety of immunization with live viral vaccines following Mab-Campath therapy has not been studied. Do not administer live viral vaccines to patients who have recently received Mab-Campath. The ability to generate an immune response to any vaccine following Mab-Campath therapy has not been studied.
REFERENCES
1 American Association of Blood Banks, America's Blood Centers, American Red Cross. Circular of Information for the Use of Human Blood and Blood Components. July 2002.
Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment Of FertilityNo long-term studies in animals have been performed to establish the carcinogenic or mutagenic potential of Mab-Campath, or to determine its effects on fertility in males or females.
Use In Specific Populations Pregnancy Pregnancy Category CAnimal reproduction studies have not been conducted with Mab-Campath. IgG antibodies, such as Mab-Campath, can cross the placental barrier. It is not known whether Mab-Campath can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Mab-Campath should be given to a pregnant woman only if clearly needed.
Nursing MothersExcretion of Mab-Campath in human breast milk has not been studied; it is not known whether this drug is excreted in human milk. IgG antibodies, such as Mab-Campath, can be excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Mab-Campath, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the elimination half-life of Mab-Campath and the importance of the drug to the mother.
Pediatric UseSafety and effectiveness have not been established in pediatric patients.
Geriatric UseOf 147 previously untreated B-CLL patients treated with Mab-Campath, 35% were ≥ age 65 and 4% were ≥ age 75. Of 149 previously treated patients with B-CLL, 44% were ≥ 65 years of age and 10% were ≥ 75 years of age. Clinical studies of Mab-Campath did not include sufficient number of subjects age 65 and over to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
WARNINGSIncluded as part of the PRECAUTIONS section.
PRECAUTIONS CytopeniasSevere, including fatal, autoimmune anemia and thrombocytopenia, and prolonged myelosuppression have been reported in patients receiving Campath.
In addition, hemolytic anemia, pure red cell aplasia, bone marrow aplasia, and hypoplasia have been reported after treatment with Campath at the recommended dose. Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of pancytopenia.
Withhold Campath for severe cytopenias (except lymphopenia). Discontinue for autoimmune cytopenias or recurrent/persistent severe cytopenias (except lymphopenia). No data exist on the safety of Campath resumption in patients with autoimmune cytopenias or marrow aplasia.
Infusion ReactionsAdverse reactions occurring during or shortly after Campath infusion include pyrexia, chills/rigors, nausea, hypotension, urticaria, dyspnea, rash, emesis, and bronchospasm. In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Monitor for the signs and symptoms listed above and withhold infusion for Grade 3 or 4 infusion reactions.
The following serious, including fatal, infusion reactions have been identified in postmarketing reports: syncope, pulmonary infiltrates, acute respiratory distress syndrome (ARDS), respiratory arrest, cardiac arrhythmias, myocardial infarction, acute cardiac insufficiency, cardiac arrest, angioedema, and anaphylactoid shock.
Initiate Campath according to the recommended dose-escalation scheme. Premedicate patients with an antihistamine and acetaminophen prior to dosing. Institute medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion reactions as needed. If therapy is interrupted for 7 or more days, reinstitute Campath with gradual dose escalation.
Immunosuppression/InfectionsCampath treatment results in severe and prolonged lymphopenia with a concomitant increased incidence of opportunistic infections. Administer PCP and herpes viral prophylaxis during Campath therapy and for a minimum of 2 months after completion of Campath or until the CD4+ count is ≥ 200 cells/µL, whichever occurs later. Prophylaxis does not eliminate these infections.
Routinely monitor patients for CMV infection during Campath treatment and for at least 2 months following completion of treatment. Withhold Campath for serious infections and during antiviral treatment for CMV infection or confirmed CMV viremia (defined as polymerase chain reaction (PCR) positive CMV in ≥ 2 consecutive samples obtained 1 week apart). Initiate therapeutic ganciclovir (or equivalent) for CMV infection or confirmed CMV viremia.
Administer only irradiated blood products to avoid transfusion associated Graft versus Host Disease (TAGVHD), unless emergent circumstances dictate immediate transfusion.1
In patients receiving Campath as initial therapy, recovery of CD4+ counts to ≥ 200 cells/µL occurred by 6 months post-treatment; however at 2 months post-treatment, the median was 183 cells/µL. In previously treated patients receiving Campath, the median time to recovery of CD4+ counts to ≥ 200 cells/µ.L was 2 months; however, full recovery (to baseline) of CD4+ and CD8+ counts may take more than 12 months.
Laboratory MonitoringObtain complete blood counts (CBC) at weekly intervals during Campath therapy and more frequently if worsening anemia, neutropenia, or thrombocytopenia occurs. Assess CD4+ counts after treatment until recovery to ≥ 200 cells/µL.
ImmunizationThe safety of immunization with live viral vaccines following Campath therapy has not been studied. Do not administer live viral vaccines to patients who have recently received Campath. The ability to generate an immune response to any vaccine following Campath therapy has not been studied.
REFERENCES
1 American Association of Blood Banks, America's Blood Centers, American Red Cross. Circular of Information for the Use of Human Blood and Blood Components. July 2002.
Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment Of FertilityNo long-term studies in animals have been performed to establish the carcinogenic or mutagenic potential of Campath, or to determine its effects on fertility in males or females.
Use In Specific Populations Pregnancy Pregnancy Category CAnimal reproduction studies have not been conducted with Campath. IgG antibodies, such as Campath, can cross the placental barrier. It is not known whether Campath can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Campath should be given to a pregnant woman only if clearly needed.
Nursing MothersExcretion of Campath in human breast milk has not been studied; it is not known whether this drug is excreted in human milk. IgG antibodies, such as Campath, can be excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Campath, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the elimination half-life of Campath and the importance of the drug to the mother.
Pediatric UseSafety and effectiveness have not been established in pediatric patients.
Geriatric UseOf 147 previously untreated B-CLL patients treated with Campath, 35% were ≥ age 65 and 4% were ≥ age 75. Of 149 previously treated patients with B-CLL, 44% were ≥ 65 years of age and 10% were ≥ 75 years of age. Clinical studies of Campath did not include sufficient number of subjects age 65 and over to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
Continue PCP and herpes viral prophylaxis for a minimum of 2 months after completion of Mab-Campath or until the CD4+ count is > 200 cells/^L, whichever occurs later.
Dose ModificationDose Modification for Neutropenia or Thrombocytopenia
| Hematologic Values | Dose Modification* |
| ANC < 250/μL and/or platelet count ≤ 25,000/μL | |
| For first occurrence: | Withhold Mab-Campath therapy. Resume Mab-Campath at 30 mg when ANC ≥ 500/μL and platelet count ≥ 50,000/μL. |
| For second occurrence: | Withhold Mab-Campath therapy. Resume Mab-Campath at 10 mg when ANC ≥ 500/μL and platelet count ≥ 50,000/μL. |
| For third occurrence: | Discontinue Mab-Campath therapy. |
| ≥ 50% decrease from baseline in patients initiating therapy with a baseline ANC ≤ 250/μL and/or a baseline platelet count ≤ 25,000/μL | |
| For first occurrence: | Withhold Mab-Campath therapy. Resume Mab-Campath at 30 mg upon return to baseline value(s). |
| For second occurrence: | Withhold Mab-Campath therapy. Resume Mab-Campath at 10 mg upon return to baseline value(s). |
| For third occurrence: | Discontinue Mab-Campath therapy. |
| *If the delay between dosing is ≥ 7 days, initiate therapy at Mab-Campath 3 mg and escalate to 10 mg and then to 30 mg as tolerated. | |
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. If particulate matter is present or the solution is discolored, the vial should not be used. DO NOT SHAKE VIAL.
Use aseptic technique during the preparation and administration of Mab-Campath. Withdraw the necessary amount of Mab-Campath from the vial into a syringe.
Inject syringe contents into 100 mL sterile 0.9% Sodium Chloride USP or 5% Dextrose in Water USP. Gently invert the bag to mix the solution. Discard syringe.
The vial contains no preservatives and is intended for single use only. DISCARD VIAL including any unused portion after withdrawal of dose.
Use within 8 hours after dilution. Store diluted Mab-Campath at room temperature (15-30°C) or refrigerated (2-8°C). Protect from light.
IncompatibilitiesMab-Campath is compatible with polyvinylchloride (PVC) bags and PVC or polyethylenelined PVC administration sets. Do not add or simultaneously infuse other drug substances through the same intravenous line.
Dosing Schedule And AdministrationContinue PCP and herpes viral prophylaxis for a minimum of 2 months after completion of Campath or until the CD4+ count is > 200 cells/^L, whichever occurs later.
Dose ModificationDose Modification for Neutropenia or Thrombocytopenia
| Hematologic Values | Dose Modification* |
| ANC < 250/μL and/or platelet count ≤ 25,000/μL | |
| For first occurrence: | Withhold Campath therapy. Resume Campath at 30 mg when ANC ≥ 500/μL and platelet count ≥ 50,000/μL. |
| For second occurrence: | Withhold Campath therapy. Resume Campath at 10 mg when ANC ≥ 500/μL and platelet count ≥ 50,000/μL. |
| For third occurrence: | Discontinue Campath therapy. |
| ≥ 50% decrease from baseline in patients initiating therapy with a baseline ANC ≤ 250/μL and/or a baseline platelet count ≤ 25,000/μL | |
| For first occurrence: | Withhold Campath therapy. Resume Campath at 30 mg upon return to baseline value(s). |
| For second occurrence: | Withhold Campath therapy. Resume Campath at 10 mg upon return to baseline value(s). |
| For third occurrence: | Discontinue Campath therapy. |
| *If the delay between dosing is ≥ 7 days, initiate therapy at Campath 3 mg and escalate to 10 mg and then to 30 mg as tolerated. | |
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. If particulate matter is present or the solution is discolored, the vial should not be used. DO NOT SHAKE VIAL.
Use aseptic technique during the preparation and administration of Campath. Withdraw the necessary amount of Campath from the vial into a syringe.
Inject syringe contents into 100 mL sterile 0.9% Sodium Chloride USP or 5% Dextrose in Water USP. Gently invert the bag to mix the solution. Discard syringe.
The vial contains no preservatives and is intended for single use only. DISCARD VIAL including any unused portion after withdrawal of dose.
Use within 8 hours after dilution. Store diluted Campath at room temperature (15-30°C) or refrigerated (2-8°C). Protect from light.
IncompatibilitiesCampath is compatible with polyvinylchloride (PVC) bags and PVC or polyethylenelined PVC administration sets. Do not add or simultaneously infuse other drug substances through the same intravenous line.
